2F5
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
2F5 (2F5) - Total Liabilities
Latest total liabilities as of June 2025: €3.98 Million EUR
Based on the latest financial reports, 2F5 (2F5) has total liabilities worth €3.98 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
2F5 - Total Liabilities Trend (2021–2024)
This chart illustrates how 2F5's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
2F5 Competitors by Total Liabilities
The table below lists competitors of 2F5 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Evolving Systems Inc
PINK:EVOL
|
USA | $1.35 Million |
|
Manydev Studio SE
WAR:MAN
|
Poland | zł4.25 Million |
|
Star Vault AB (publ)
PINK:SRVTF
|
USA | $849.62K |
|
TVD Holdings PCL
BK:TVDH
|
Thailand | ฿626.42 Million |
|
Aruma Resources Ltd
AU:AAJ
|
Australia | AU$128.20K |
|
Acticor Biotech SAS
PA:ALACT
|
France | €15.51 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 2F5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 2F5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 2F5 (2021–2024)
The table below shows the annual total liabilities of 2F5 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.47 Million | -84.25% |
| 2023-12-31 | €22.04 Million | -23.54% |
| 2022-12-31 | €28.83 Million | -7.17% |
| 2021-12-31 | €31.05 Million | -- |